What is the summary of : Shaping the future of global access to
safe, effective, appropriate and quality
health products
Introduction:
Everyone should have access to essential health products according to treaties.
Before COVID-19, 2 billion people lacked essential medicines, and many low- and middle-income countries (LMICs) lacked basic diagnostic services.
The pandemic worsened these issues, revealing problems in health product distribution and access.
Lessons from the Past:
In 2000, many people in LMICs couldn’t access HIV medicines due to high prices from pharmaceutical monopolies.
Activists fought for affordable HIV treatment, leading to changes in policies and access.
Despite past successes, similar efforts haven’t been made for other diseases, leading to high prices and limited access for many new treatments.
Current Issues:
COVID-19 highlighted global inequities in vaccine access.
High costs and monopolies still limit access to new medicines, even in wealthy countries.
Poor regulatory systems and weak supply chains in some countries lead to unsafe medicines and treatment gaps.
Four Key Areas for Improvement:
Pharmaceutical Innovation Ecosystem:
- Rethink how medicines are developed and priced to ensure they meet public health needs.
- Encourage local production and technology sharing.
Health Sector Prioritization:
- Use evidence-based methods to decide which health products are most important.
- Ensure that resources are used effectively and equitably.
Regulatory and Supply Systems:
- Strengthen systems to ensure all health products are safe and available.
- Address issues of poor quality and stock shortages.
Universal Health Coverage:
- Make health products affordable for everyone, reducing reliance on out-of-pocket payments.
– Implement inclusive health insurance systems and ensure public funding for health.
Conclusion:
- Equitable access to quality health products is still not a reality.
-Essential health products should be treated as common goods, not commercial assets.
- International efforts should focus on public health goals and equity, with investments in LMICs to develop and access health solutions
